Frontage Labs plans to expand its chemistry, manufacturing and controls (CMC) facility in Exton, Pa., to significant increase capacity to existing services and provide additional room for future growth.

The renovation plan involves two phases. Initial enhancements, which include two analytical laboratories and 8,000 square feet of office space, will begin in mid-2014, to be completed by the end of September. The second phase, which includes additional clinical trial manufacturing (CTM) space for solid, semi-solid and sterile products, packaging, labeling and distribution functions, will begin in 2015, to be completed in mid-2015. Upon completion, Frontage expects to increase its CMC workforce and capacity by more than 50%.

Frontage’s CMC service portfolio includes organic synthesis, formulation development, GMP analytical testing and GMP clinical trial material manufacturing, for drug candidates ranging from novel, early phase projects to generic-equivalent and consumer care medications. Frontage has developed oral solid, semi-solid, liquid and sterile dosage forms that have been evaluated in clinical research programs and commercialized in the U.S., E.U. and Asian markets by its clients.